Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lisinopril Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 8/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lisinopril Anhydrous SCHEMBL454824 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL29047795 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL677321 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL1268274 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL31692087 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2F2 | |
| Lisinopril Anhydrous SCHEMBL24062681 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL15680 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL156900 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL7268245 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL18712916 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747611-A1 | OPTICAL ELECTRODE ANALYTE DETECTION SYSTEM AND METHODS OF USE | Vital Biosciences Inc. (CA) | 2026-05-27 | — | — | EP | claimed |
| US-12433931-B2 | Lisinopril formulations | AZURITY PHARMACEUTICALS, INC. (US) | 2025-10-07 | — | — | US | claimed |
| US-20250186533-A1 | LISINOPRIL FORMULATIONS | Silvergate Pharmaceuticals, Inc. | 2025-06-12 | — | — | US | claimed |
| WO-2025022286-A1 | OPTICAL ELECTRODE ANALYTE DETECTION SYSTEM AND METHODS OF USE | VITAL BIOSCIENCES INC. (CA) | 2025-01-30 | — | — | WO | claimed |
| US-12186360-B2 | Lisinopril formulations | AZURITY PHARMACEUTICALS, INC. (US) | 2025-01-07 | — | — | US | claimed |
| US-12128083-B2 | Lisinopril formulations | AZURITY PHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | claimed |
| US-20240335374-A1 | COMPOSITIONS FOR ANTIHYPERTENSIVE DRUGS | INNOVATOR THERAPEUTICS, LLC | 2024-10-10 | — | — | US | claimed |
| WO-2024210922-A1 | COMPOSITIONS FOR ANTIHYPERTENSIVE DRUGS | INNOVATOR THERAPEUTICS, LLC. (US) | 2024-10-10 | — | — | WO | claimed |
| US-20240299485-A1 | LISINOPRIL FORMULATIONS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-09-12 | — | — | US | claimed |
| US-20230405079-A1 | LISINOPRIL FORMULATIONS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2023-12-21 | — | — | US | claimed |
| EP-1765342-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE BESILATE AND LISINOPRIL DIHYDRATE AND PROCESS FOR THE PREPARATION THEREOF | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2007-03-28 | — | — | EP | claimed |
| WO-2005120502-A1 | NEW PHARMACEUTICAL COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2005-12-22 | — | — | WO | claimed |
| EP-1424998-A4 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | UNIV PENNSYLVANIA (US) | 2005-11-23 | — | — | EP | claimed |
| US-20050069577-A1 | Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies | TRUSTEES OF UNIVERSITY OF PENNSYLVANIA | 2005-03-31 | — | — | US | claimed |
| EP-1432407-B1 | LISINOPRIL COMPOSITIONS HAVING LARGE-PARTICLE DCPD | ASTRAZENECA UK LTD (GB) | 2005-03-09 | — | — | EP | claimed |
| EP-1432407-A1 | LISINOPRIL COMPOSITIONS HAVING LARGE-PARTICLE DCPD | AstraZeneca UK Limited (GB) | 2004-06-30 | — | — | EP | claimed |
| EP-1424998-A1 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | The Trustees of The University of Pennsylvania (US) | 2004-06-09 | — | — | EP | claimed |
| WO-2003026622-A1 | LISINOPRIL COMPOSITIONS HAVING LARGE-PARTICLE DCPD | ASTRAZENECA AB (SE) | 2003-04-03 | — | — | WO | claimed |
| WO-2003015757-A1 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2003-02-27 | — | — | WO | claimed |
| US-6462022-B1 | INCREASED SHELF LIFE OF TABLETS FORMULATED WITH THE LARGER SIZED DIBASIC CALCIUM PHOSPHATE DIHYDRATE PARTICULARLY AT LOW DRUG DOSAGE; REDUCED DEGRADATION TO DIKETOPIPERAZINE | ASTRAZENECA AB (SE) | 2002-10-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12186360-B2 | Lisinopril formulations | REN, ACE, AGT | ACE 2/4885LMNA 174/4885SMN1; SMN2 1363/4885 |
| US-20240299485-A1 | LISINOPRIL FORMULATIONS | REN, ACE, AGT | ACE 2/4885LMNA 174/4885SMN1; SMN2 1363/4885 |
| US-12433931-B2 | Lisinopril formulations | REN, ACE, AGT | ACE 2/4885LMNA 174/4885SMN1; SMN2 1363/4885 |
| US-12128083-B2 | Lisinopril formulations | REN, ACE, AGT | ACE 2/4885LMNA 174/4885SMN1; SMN2 1363/4885 |
| US-20250186533-A1 | LISINOPRIL FORMULATIONS | REN, ACE, AGT | ACE 2/4885LMNA 174/4885SMN1; SMN2 1363/4885 |
| US-20230405079-A1 | LISINOPRIL FORMULATIONS | REN, ACE, AGT | ACE 2/4885LMNA 174/4885SMN1; SMN2 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.